With this introduction, Aurobindo Pharma now offers more product options for the treatment of Aids than any other pharma company.

"Imunus, the antiretroviral division was launched by Aurobindo about five months ago, and in a short time has been able to offer wider product options than any other pharma company. Further, all these products are competitively priced reducing the overall cost of HIV treatment." said Mr Hariharan, Vice President, Aurobindo Pharma.

Aurobindo Pharma is able to offer these drugs at such competitive prices on account of its large scale bulk manufacturing facilities as well as strong in-house R&D capabilities.

Aurobindo's R&D is further working on developing fixed dose combination forms to reduce pill burden. This will enable patients to adhere to the dosage of the medicines, improve compliance and will further bring down the overall cost of treatment.

Mr Hariharan emphasised that Imunus would soon start marketing antivirals, antibiotics and antifungal preparations for all other infections associated with HIV/AIDS.